To include your compound in the COVID-19 Resource Center, submit it here.

INS365 ophthalmic drops: Phase III data

In a double-blind, 6-month U.S. Phase III trial (study 105) in 527 patients with dry eye, INS365 2% ophthalmic drops

Read the full 207 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE